Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking моноклональный антитело that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1+ клетка lines, including lymphoma cells.
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1+ cell lines, including lymphoma cells.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.